DES Rates Sustained, CMS Exerting Price Pressures: Payment Recap

Johnson & Johnson/Cordis' efforts to raise the drug-eluting stent inpatient payment rates fell short in 2003, paving the way for the Cypher manufacturer and imminent competitor Boston Scientific (Taxus) to wage a concerted lobbying campaign this year